Protein kinase inhibitor

Branebrutinib: A Agammaglobulinaemia Tyrosine Kinase Inhibitors by Bristol Myers Squibb - Global Emerging Insight and Market Forecast 2021-2030 - ResearchAndMarkets.com

Retrieved on: 
Thursday, March 11, 2021
Health, Pharmaceutical, Bristol Myers Squibb, Protein kinase inhibitor, Tyrosine kinase inhibitor, Companies, Life sciences, Industry economics)

"Branebrutinib- Emerging Insight and Market Forecast - 2030" the report provides comprehensive insights about an investigational product for Sjogren's syndrome in 7 Major Markets.

Key Points: 
  • "Branebrutinib- Emerging Insight and Market Forecast - 2030" the report provides comprehensive insights about an investigational product for Sjogren's syndrome in 7 Major Markets.
  • Further, it also consists of future market assessments inclusive of the market forecast, SWOT analysis, market competitors, and other emerging therapies.
  • Branebrutinib acts as Agammaglobulinaemia tyrosine kinase inhibitors.
  • It is currently in Phase II of clinical trial study for Sjogren's syndrome and is being developed by Bristol Myers Squibb.

Eisai: MHLW Grants Orphan Drug Designation in Japan to Novel FGF Receptor Selective Tyrosine Kinase Inhibitor E7090

Retrieved on: 
Monday, February 22, 2021
Tyrosine kinase receptors, Clusters of differentiation, Branches of biology, Cell biology, Biology, Fibroblast growth factor receptor 2, Fibroblast growth factor receptor 1, Fibroblast growth factor receptor, Fibroblast growth factor, Tyrosine kinase, Cholangiocarcinoma, Protein kinase inhibitor

In Japan, a Phase I clinical trial of E7090 was conducted, and E7090 has been designated as the target drug for the SAKIGAKE Designation System of the MHLW for the treatment of unresectable biliary tract cancer.

Key Points: 
  • In Japan, a Phase I clinical trial of E7090 was conducted, and E7090 has been designated as the target drug for the SAKIGAKE Designation System of the MHLW for the treatment of unresectable biliary tract cancer.
  • Discovered in-house by Eisai's Tsukuba Research Laboratories, E7090 is an orally available novel tyrosine kinase inhibitor that demonstrates selective inhibitory activity against fibroblast growth factor receptors (FGFR) FGFR1, FGFR2 and FGFR3.
  • et al., "Biliary tract cancer registry in Japan from 2008 to 2013", J Hepatobiliary Pancreat Sci., 2016, 23, 149-157.
  • (6) Arai Y. et al., "Fibroblast growth factor receptor 2 tyrosine kinase fusions define a unique molecular subtype of cholangiocarcinoma", Hepatology, 2014, 59, 1427-1434.

Kinnate Biopharma Inc. to Participate in Upcoming Investor Conferences

Retrieved on: 
Thursday, February 11, 2021
Antineoplastic drugs, SVB Leerink, Targeted therapy, Kinase, Protein kinase inhibitor, Cancer, Companies

A live webcast of the SVB Leerink presentation will be available in the Investors and Media section of the Kinnate website at www.kinnate.com .

Key Points: 
  • A live webcast of the SVB Leerink presentation will be available in the Investors and Media section of the Kinnate website at www.kinnate.com .
  • Kinnate is focused on the discovery and development of small molecule kinase inhibitors for difficult-to-treat, genomically defined cancers.
  • Kinnate utilizes its deep expertise in structure-based drug discovery, translational research, and patient-driven precision medicine, which it refers to as the Kinnate Discovery Engine, to develop targeted therapies.
  • All statements other than statements of historical facts contained in this press release are forward-looking statements, including, without limitation, Kinnates expected participation at investor conferences.

Apollomics, Inc. and Edison Oncology Announce Licensing Agreement for Novel Protein Tyrosine Kinase Inhibitor Targeting Solid Tumors

Retrieved on: 
Wednesday, February 10, 2021
Tyrosine kinase receptors, Oncogenes, Branches of biology, Cancer, ErbB, Epidermal growth factor receptor, HER2/neu, Protein kinase inhibitor, Tyrosine kinase, ERBB4, Spectrum Pharmaceuticals, AEE788

EO1001 is a protein tyrosine kinase inhibitor (TKI) that has demonstrated irreversible inhibition of EGFR (ErbB1), HER2 (ErbB2) and HER4 (ErbB4) as a single agent.

Key Points: 
  • EO1001 is a protein tyrosine kinase inhibitor (TKI) that has demonstrated irreversible inhibition of EGFR (ErbB1), HER2 (ErbB2) and HER4 (ErbB4) as a single agent.
  • Under the terms of the agreement, Apollomics has the exclusive rights to develop and commercialize EO1001 globally, except in China, Hong Kong and Taiwan.
  • EO1001 is a protein tyrosine kinase inhibitor (TKI) that has demonstrated irreversible inhibition of EGFR (ErbB1), HER2 (ErbB2) and HER4 (ErbB4) as a single agent.
  • Edison Oncology was founded in 2018 by experienced life science industry veterans to develop and commercialize new therapies targeting the fight against cancer.

Apollomics, Inc. and Edison Oncology Announce Licensing Agreement for Novel Protein Tyrosine Kinase Inhibitor Targeting Solid Tumors

Tyrosine kinase receptors, Oncogenes, Branches of biology, Cancer, ErbB, Epidermal growth factor receptor, HER2/neu, Protein kinase inhibitor, Tyrosine kinase, ERBB4, Spectrum Pharmaceuticals, AEE788

EO1001 is a protein tyrosine kinase inhibitor (TKI) that has demonstrated irreversible inhibition of EGFR (ErbB1), HER2 (ErbB2) and HER4 (ErbB4) as a single agent.

Key Points: 
  • EO1001 is a protein tyrosine kinase inhibitor (TKI) that has demonstrated irreversible inhibition of EGFR (ErbB1), HER2 (ErbB2) and HER4 (ErbB4) as a single agent.
  • Under the terms of the agreement, Apollomics has the exclusive rights to develop and commercialize EO1001 globally, except in China, Hong Kong and Taiwan.
  • EO1001 is a protein tyrosine kinase inhibitor (TKI) that has demonstrated irreversible inhibition of EGFR (ErbB1), HER2 (ErbB2) and HER4 (ErbB4) as a single agent.
  • Edison Oncology was founded in 2018 by experienced life science industry veterans to develop and commercialize new therapies targeting the fight against cancer.

World-Renowned Cancer Researcher, Dr. Alan Ashworth, Joins Phoenix Molecular Designs Advisory Board

Retrieved on: 
Thursday, February 4, 2021
Branches of biology, Biology, Signal transduction, P110α, Ribosomal s6 kinase, Alan Ashworth, Cancer, Breast cancer, RSK, Phosphoinositide 3-kinase, Small molecule, Protein kinase inhibitor

SAN DIEGO and VANCOUVER,BC, Feb. 4, 2021 /PRNewswire/ - Phoenix Molecular Designs (PhoenixMD), an industry leader in the development of precise cancer therapeutics focusing on first-in-class RSK kinase inhibitors, today announced the appointment of Dr. Alan Ashworth PhD, FRS to their Advisory Board as a Scientific Advisor.

Key Points: 
  • SAN DIEGO and VANCOUVER,BC, Feb. 4, 2021 /PRNewswire/ - Phoenix Molecular Designs (PhoenixMD), an industry leader in the development of precise cancer therapeutics focusing on first-in-class RSK kinase inhibitors, today announced the appointment of Dr. Alan Ashworth PhD, FRS to their Advisory Board as a Scientific Advisor.
  • His team identified RSK2 using unbiased functional screens in search of novel drug targets for specific breast cancer subtypes.
  • This research launched Phoenix Molecular Designs in 2012, the only company to have developed a first-in-class small molecule against RSK.
  • Moreover, in the same article that highlighted RSK2 as a target for TNBC, Alan also identified PIK3CA as a target for luminal breast cancer.

Eisai to Present Abstracts on Lenvatinib at 2021 Gastrointestinal Cancers Symposium

Retrieved on: 
Tuesday, January 12, 2021
Chemical compounds, Organic compounds, Orphan drugs, Chloroarenes, Cyclopropanes, Lenvatinib, Ureas, Eisai, Chemistry, Protein kinase inhibitor, Merck & Co., Cancer

TOKYO, Jan 12, 2021 - (JCN Newswire) - Eisai Co., Ltd. has announced that presentations on a series of abstracts highlighting updates on its in-house discovered lenvatinib mesylate (product name: LENVIMA, the orally available kinase inhibitor, "lenvatinib") will be given at the Gastrointestinal Cancers Symposium Virtual Meeting, from January 15 to 17, 2021.

Key Points: 
  • TOKYO, Jan 12, 2021 - (JCN Newswire) - Eisai Co., Ltd. has announced that presentations on a series of abstracts highlighting updates on its in-house discovered lenvatinib mesylate (product name: LENVIMA, the orally available kinase inhibitor, "lenvatinib") will be given at the Gastrointestinal Cancers Symposium Virtual Meeting, from January 15 to 17, 2021.
  • In March 2018, Eisai and Merck & Co., Inc., Kenilworth, N.J., U.S.A., through an affiliate, entered into a strategic collaboration for the worldwide co-development and co-commercialization of lenvatinib.
  • Eisai positions oncology as a key therapeutic area, and is aiming to discover revolutionary new medicines with the potential to cure cancer.
  • Eisai aspires to discover innovative new drugs with new targets and mechanisms of action from these Ricchi, with the aim of contributing to the cure of cancers.

Onconova Therapeutics Announces FDA Permission for Study to Proceed Under its Investigational New Drug Application for Multi-kinase CDK4/6 Inhibitor ON 123300

Retrieved on: 
Monday, December 21, 2020
Branches of biology, Cell Cycle, Biology, Kinase, Cyclin-dependent kinase 4, Protein kinase inhibitor, Enzymes

We are grateful to receive this timely, favorable response from the FDA to initiate a Phase 1 trial with ON 123300, said Steven M. Fruchtman, M.D., President and Chief Executive Officer of Onconova.

Key Points: 
  • We are grateful to receive this timely, favorable response from the FDA to initiate a Phase 1 trial with ON 123300, said Steven M. Fruchtman, M.D., President and Chief Executive Officer of Onconova.
  • Additional patient cohorts are under consideration, including but not limited to patients diagnosed with advanced colorectal cancer, and non-Hodgkins lymphoma, in particular mantle cell lymphoma.
  • Onconovas lead pipeline compound is the novel small molecule ON 123300, a proprietary, first-in-class multi-kinase inhibitor targeting tumor-driving kinases including CDK4/6 and ARK5.
  • Onconova Therapeutics is a biopharmaceutical company focused on discovering and developing novel products to treat cancer.

Turning Point Therapeutics Granted FDA Breakthrough Therapy Designation for Repotrectinib Treatment in Patients with ROS1-Positive Metastatic Non-Small Cell Lung Cancer Who Have Not Been Treated with a ROS1 Tyrosine Kinase Inhibitor

Retrieved on: 
Tuesday, December 8, 2020
Tyrosine kinase receptors, Lung cancer, Chemical compounds, ROS1, Organic compounds, Tyrosine kinase inhibitors, Non-small-cell lung carcinoma, Heterocyclic compounds, Protein kinase inhibitor, Orphan drugs, ALK inhibitor, Entrectinib

Turning Point plans to present updated TRIDENT-1 Phase 2 study data from patients with TKI-naive ROS1-positive NSCLC during a mini-oral presentation at the World Conference on Lung Cancer on Jan. 31, 2021.

Key Points: 
  • Turning Point plans to present updated TRIDENT-1 Phase 2 study data from patients with TKI-naive ROS1-positive NSCLC during a mini-oral presentation at the World Conference on Lung Cancer on Jan. 31, 2021.
  • Breakthrough therapy designation is granted by the FDA to expedite the development and regulatory review of an investigational medicine that is intended to treat a serious or life-threatening condition.
  • The companys lead drug candidate, repotrectinib, is a next-generation kinase inhibitor targeting the ROS1 and TRK oncogenic drivers of non-small cell lung cancer and advanced solid tumors.
  • The company is driven to develop therapies that mark a turning point for patients in their cancer treatment.

Kinnate Biopharma Announces Closing of Initial Public Offering and Exercise in Full of the Underwriters’ Option to Purchase Additional Shares

Retrieved on: 
Monday, December 7, 2020
Companies, Banks of the United States, Banks, SVB Leerink, Goldman Sachs, Piper Sandler Companies, Protein kinase inhibitor

Including the option exercise, the aggregate gross proceeds from the offering were $276.0 million, before deducting underwriting discounts and commissions and estimated offering expenses.

Key Points: 
  • Including the option exercise, the aggregate gross proceeds from the offering were $276.0 million, before deducting underwriting discounts and commissions and estimated offering expenses.
  • The shares began trading on The Nasdaq Global Select Market on December 3, 2020, under the symbol KNTE.
  • Goldman Sachs & Co. LLC, SVB Leerink LLC and Piper Sandler & Co. acted as joint book-running managers for the offering.
  • Kinnate Biopharma is focused on the discovery and development of small molecule kinase inhibitors for difficult-to-treat, genomically defined cancers.